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Acanthocytuna
Diagnosis 255
ACE inhibitors see under Converting
enzyme inhibitors
ACE inhibitors see also more specific






Antagonists and inhibitors 552
Physiology 379, 550, 570
Acid-base imbalance 265, 532
Acid-base regulation. 263, 282, 393, 539, 544





Pathophysiology . 266, 268, 274, 448, 453,
464, 468, 505, 531, 534,







Pathophysiology 448, 540, 545, 547
Acquired immunodeficiency syndrome see
under AIDS
Acquired immunodeficiency syndrome see
also HIV infection
Actin 224, 225





Epidemiology 273, 277, 284
Etiology 238, 259, 282
Mortality 273
Pathology 493
Pathophysiology . 278, 350, 475, 476, 477,
479, 480, 481, 482, 483,
484, 485, 486, 488, 489,
490, 491, 492, 493, 494,
496, 497





Pathophysiology .. 478, 480, 487 488, 496
Prevention and control 480
Adenosine
Pharmacology 477
Physiology 364, 381, 556, 612
Receptors 380, 381
Transport 476
Adenosine see also ATP
Adenyl cyclase
Antagonists and inhibitors 207
Isolation and purification 215
Physiology . . 361, 364, 388, 463, 574, 592
Adenyl cyclase see also Cyclic AMP
ADH see also SIADH
ADH see under Vasopressins
ADPases 407
ADPases see also ATPases
Adrenal glands 369
Adrenergic agonists, alpha-2 579
Adrenergic blockers, alpha








Aging 272, 340, 498, 517
AIDS 325
AIDS see also HIV infection
AIDS nephropathy 254
Alanine 530, 577
Albumin excretion 245, 285, 347










Physiology 356, 588, 590
Aldosterone
Antagonists and inhibitors 353
Pharmacology 353
Physiology. . 227, 233, 264, 358, 359, 548,
562, 563, 564, 575
Regulation 205, 356






Prevention and control 318

















Physiology.. 294, 449, 450, 451, 452, 471,
472
Toxicity. . . . 286, 289, 291, 292, 295, 296,
299, 301, 305, 308, 309, 328, 449,




Ambulatory blood pressure monitoring . 398
Amioride
Analogs and derivatives 1%
Pharmacology 577
Amino acid sequence 382
Amino acid transport, sodium dependent 230
Amino acids
Analogs and derivatives 511




Amino acids see also more specific entries
Amino acids, branched chain 509
Aminoguanidine 506
Aminophylline 335
Aminophylline see also Theophylline
Ammonia




Transport. . . 264, 535, 536, 540, 542, 543,
547, 562, 583
Ammoniagenesis
Antagonists and inhibitors 212
Ammonium chloride 530
Amphotericin B 285, 493
Amphotericin nephropathy.... 484, 493, 494










Drug therapy. . . . 236, 237, 240, 244, 245,
271, 288, 293, 298, 299, 312,
313, 332, 378, 520
Etiology 240, 316, 507, 604
Pathophysiology 286, 308, 473, 511
Surgery 321
Angioplasty see under Percutaneous
transluminal angioplasty
Angiotensin converting enzyme see under
Converting enzyme
Angiotensins
Antagonists and inhibitors . 354, 359, 382,
557
Metabolism 354
Pharmacology 355, 358, 479, 592
Physiology. . 211, 213, 346, 350, 353, 354,
356, 359, 360, 378, 537, 541,
543, 548, 550, 552, 555, 556,
557, 571
Receptors 204, 359, 360, 476
Angiotensins see also Converting enzyme
Angiotensins see also Renin-angiotensin
system
Anion gap 265, 267, 268
Anion gap see also Osmolar gap
Anions, organic 546




Anoxia 482, 490, 492, 493, 495, 529
Anoxia see also Hypoxia, ischemia,
reperfusion injury




Classification 441, 442, 444
Diagnostic use 440, 443
Immunology 441, 444
Physiology 441, 442
Antibodies see under specific entries,
(antibody to)
Antibodies see also Monoclonal antibodies
Antibody formation 438, 607













Isolation and purification 441, 444
Receptors 208
Antigens see also more specific entries
Antihypertensive agents 519









Antiport, C1/HC03 ... 214, 388, 534, 536,
549, 579
Antiport, Na/Ca". 207, 210, 396, 461, 584





Antagonists and inhibitors 191, 343
Genetics 233, 384, 539, 540
Hormone effects 537, 547
Isolation and purification 233
Pathophysiology 199, 200, 394
Physiology 199, 226
Regulation . . 214, 228, 234, 353, 361, 371,
539, 560, 578
Antiport, Na/HCO 529
Antiport, Na/K 510, 591




Apical membranes see under Cell
membranes (apical)




Metabolism 206, 344, 350, 351
Pharmacology 348, 492
Regulation 214
Arachidonic acids see also Eicosanoids
Arginine 528
Arginine see also Methyl arginine
Arrhythmias 237
Arterioles 367, 373






Pathophysiology 212, 280, 287, 512
Prevention and control 609






















Hormone effects 190, 571
Physiology. . 487, 528, 560, 565, 567, 568,
574, 575
Regulation 193, 349, 368, 481, 525
Nat, K ATPase
see also Antiport, Na/K4
Na, K ATPase inhibitors 210, 297
Physiology 386, 396
ATPases see also ADPases
Atrial natriuretic factor




Drug effects 338, 342, 343
Hormone effects 336
Pharmacology 481, 586, 596
Physiology. . 199, 251, 267, 314, 335, 336,
337, 338, 339, 340, 341, 343,
375, 378, 503, 522, 523, 553,
574
Receptors. . . 335, 337, 339, 341, 342, 344,
382
Regulation 217, 340, 362
Secretion 275, 284, 340, 343
Therapeutic use 341, 495
Atrial natriuretic factor see also Brain
natriuretic peptide




Isolation and purification 429
Autoantigens 418
Autoimmune diseases 432






Pathophysiology . 222, 377, 406, 409, 413,
414, 415, 421, 423, 424,
425, 428, 429, 432, 434,
435, 437
Regulation 406
Autoimmune injury see also Renal injury,
glomerular injury
Autoimmunity 351, 410, 445









Band 3 proteins 224, 547
Baroreflex 392, 553
Basement membrane
Anatomy and histology 246, 253
Antibody to 415, 427, 435
Drug effects 442
Genetics 218, 219
Immunology 437, 441, 446
Pathophysiology 507
Physiology 281, 592, 593
Radionudide imaging 408
Ultrastructure 447
Basement membrane see also Anti-GBM
antibody





Bence Jones proteins 494









Transport. . 386, 467, 535, 536, 537, 538,
541, 542, 544, 545, 546, 548, 572
Bicarbonates see also Antiport, C1/HC03,
Potassium, Sodium/bicarbonate symport,
Sodium bicarbonate
Binding sites 201, 293
Biocompatibility of materials 290, 308
Immunology 288
Pathophysiology 300, 316, 322, 325
Biocompatibility of materials see also
Dialysis membranes, catheters







Bleeding time 294, 322
Blood coagulation disorders
Drug therapy 294
Blood coagulation disorders see also more
specific entries
Blood coagulation factors 381, 524
Blood coagulation factors see also more
368 specific entries
Blood coagulation physiology





Physiology 386, 389, 390, 405
Regulation 339, 361, 386, 395






Therapeutic use 598, 608
Blood viscosity 271






Bone & bones 448, 452




Bone diseases see under more specific





Bone mineral content 451










Physiology 383, 389, 586, 591
Secretion 321
Brain adaptation 269
Brain dysfunction (in CRF) see under
Encephalopathy in CRF
Brain edema 268
Brain natriuretic peptide 321
Brain neoplasms 259










Calcitonin gene-related peptide 314
Calcitriol
Adverse effects 452
Analogs and derivatives 464
Biosynthesis 465, 466, 470
Metabolism 467, 469
Pharmacology 391, 513




Therapeutic use. . 391, 451,463, 464, 465,
468
Calcitriol see also Vitamin D
Calcium
Antagonists and inhibitors 452, 485
Hormone effects 387, 473, 518
Intracellular. 205, 210, 211, 213, 362, 371,
487, 576, 594, 595
Metabolism 390, 399, 405, 455, 475
Pharmacokinetics 478
Pharmacology 494
Physiology. . 210, 283, 290, 293, 302, 324,
367, 388, 390, 391, 407, 454,
456, 460, 462, 468, 470, 505,
541, 546, 553, 561, 564, 567
Regulation . . 206, 207, 208, 209, 211, 213,
216, 396, 458, 461, 470, 590
Therapeutic use . . 274, 296, 388, 402, 481
Transport. . . 337, 372, 393, 456, 457, 458,
460, 461, 464, 467, 468, 471, 486,
584
Calcium see also Antiport, Na/Ca +
Calcium acetate 449
Calcium binding protein 471
Calcium carbonate
Administration and dosage 304
Adverse effects 450
Pharmacology 456
Therapeutic use 451, 452, 455
Calcium channel blockers 268
Calcium channel blockers see also more





Physiology . . 205, 387, 454, 456, 458, 584
Regulation 205, 211, 213, 487
Calcium excretion 393
Calcium gluconate 403
Calcium oxalate 459, 462, 471
Antagonists and inhibitors 462, 474
Calcium oxalate see also Oxalates
Calmodulin 370
Calmodulin-dependent kinase
Antagonists and inhibitors 1%
CAPD see under Dialysis, peritoneal
(CAPD)
Captopril
Pharmacology . . . 271, 355, 390, 516, 523,
524
Therapeutic use 242, 261, 551
Captopril renography 398, 404, 405
644 Subject Index: Abstracts
Carbohydrates see under more specific
entries (Dietary carbohydrates, glucose,
mannose, etc.)
Carbon dioxide 535, 541
Carbonic anhydrase 533, 540
Carbonic anhydrase inhibitors 545
Cardiac output 283, 517
Cardiac tamponade 284, 312
Cardiovascular diseases
Mortality 241, 283




Carpal tunnel syndrome 305
Carrier proteins 454
Catecholamines 362, 383, 396, 398, 479
Catecholamines see also more specific
entries





Prevention and control 335
Catheters see also Dialysis catheters
Catheters, intravascular 307
cDNA 359, 584
Isolation and purification... 232, 233, 430
Cell adhesion 219, 223, 308
Cell communication (intercellular) 228
Cell culture techniques.. 194, 200, 201, 217,
221, 228, 231, 416
Cell differentiation 194, 197, 198, 222
Cell division 335, 367
Cell fusion 228




Regulation 191, 198, 204, 217, 500




Regulation 211, 583, 585, 593
Transport 226
Cell membranes 201, 408, 426
Cell membranes (apical)
Hormone effects 205, 227
Immunology 415
Metabolism 490
Physiology. . 216, 217, 227, 458, 533, 534,
560, 583, 585, 590, 592
Transport 225, 230, 559
Cell membranes (basolateral) 214, 215,
217, 458, 533, 534, 538, 543, 545, 546, 563,
584, 590, 591
Cell membranes (brush border)
Anatomy and histology 232
Drug effects 578
Immunology 445
Isolation and purification 527
Metabolism 529
Physiology. . 207, 215, 225, 343, 455, 457,
460, 462, 465, 585, 589, 593
Transport 234
Cell membranes see also Membrane fluidity,
potentials, proteins, etc.
Cell migration 408
Cell polarity (onentation) .... 215, 222, 229,
533, 538
Physiology 209, 216, 224, 586, 587
Cell proliferation.... 192, 195, 203, 509, 516
Regulation . . 197, 199, 201, 202, 204, 350,
408, 410, 412, 414, 417, 426,
436, 490
Cell volume 226, 560, 571, 573
Regulation . . 216, 564, 567, 573, 576, 579,
580, 581, 586, 590
Cellular electrophysiology. ... 232, 369, 439,
563, 564, 565, 570,
576
Cellular electrophysiology see also
Membrane potentials
Cellular immunity 423, 428, 443, 599
Cellular immunity see also Lymphocytes,
Immunologic cytotoxicity
Cellular transport mechanisms.... 487, 533,
573, 593
Hormone effects 534, 573
Regulation . . 229, 372, 383, 459, 538, 559,
568, 569
Cellular transport mechanisms see also
Antiport, Endocytosis, specific substances
(transport)
Central pontine myelinolysis 262
Cerebral aneurysm 249
Cerebral blood flow 295, 303
Cerebral hemorrhage 295
Cerebral infarction 394




Chloride channels .. 211, 215, 216, 564, 570,
571
Chlorides 396, 570, 579
Antagonists and inhibitors 365
Physiology 544, 569
Secretion 566, 581
Transport. . . 363, 377, 380, 386, 389, 396,
539, 559, 563, 566, 567, 575, 586
Chlorides see also Antiport, Cl/HC03
Cholera toxin 561
Cholesterol 207, 280, 324
Biosynthesis 520
Blood 499, 502, 512
Physiology 371, 514, 515





Chromatography 233, 234, 459
Chromogranins 382, 394, 469
Chronic renal failure
Complications. . . 237, 238, 240, 245, 464,
507, 516, 551
Diagnosis 255
Diet therapy 239, 243, 499
Drug effects 401
Drug therapy 242, 399, 498
Genetics 253, 420
Immunology 438, 439, 443
Mortality 241
Outcome 399
Pathophysiology . 235, 257, 285, 312, 384,
467, 470, 499, 504, 505,
521, 531
Therapy 330
Chronic renal failure see also End-stage
renal disease, Progression of renal
disease, Uremia
Ciprofloxacin 259

















Methods 191, 232, 233, 234
Clubbing (fingers) 448
Coagulation disorders, factors, physiology
see under Blood coagulation disorders,
etc.
Colchicine 422
Collagen vascular diseases see under
Connective tissue disorders
Collagens
Biosynthesis. 195, 218, 220, 221, 222, 344,









Colony stimulating factors 205, 424
Coma 267
Complement
Diagnostic use 243, 444
Immunology 412, 429






Pathophysiology . 288, 299, 300, 302, 319,
599













Pathophysiology. . 267, 269, 275, 337, 571
Connective tissue disorders
Drug therapy 278, 402
Constipation 272
Contrast media 260, 282, 480, 483, 484,
489, 492
Contrast nephropathy 282
Converting enzyme (ACE) inhibitors... 342,
348, 382
Converting enzyme (ACE) inhibitors see
also more specific entries
Converting enzyme (angiotensin) 355,
356, 359
Coronary artery disease 243
Coronary artery disease see also
Cardiovascular diseases, heart diseases
Cortex, renal see under Renal cortex
Cortisol 384
Costs & cost analysis 241, 520
Creatinine
Blood 241, 248, 249
Metabolism 531




Cuprophane see under Dialysis membranes,
cuprophane
Cyclic AMP 362, 365, 379, 460, 576
Physiology. . 202, 206, 209, 216, 226, 464,
536, 586
Receptors 367
Cyclic AMP see also Adenyl cyclase
Cyclic GMP 335, 336, 338, 343, 360
Cyclic GMP see also Guanyl cyclase
Cyclo-oxygenase (prostaglandin synthase)
Antagonists and inhibitors . 345, 346, 348,
365
Physiology 192, 347, 351, 375
Cyclophosphamide 238, 256
Cyclosporine nephropathy
Diagnosis 260, 482, 496, 610
Epidemiology 482
Pathology 493, 600
Pathophysiology . 190, 477, 479, 483, 485,




Adverse effects . . 266, 391, 392, 403, 475,
598, 605, 608, 613
Immunology 601
Metabolism 600
Pharmacology . . . 193, 365, 391, 595, 597,
598, 602, 607
Therapeutic use. . 255, 442, 482, 483, 489,
603, 606, 613
Toxicity. . . . 190, 234, 260, 285, 493, 594,
595, 597, 607, 610, 612
Cystatin 500
Cyst decompression surgery 247
Cyst(ic) development/formation... 190, 225,
412, 581
Cyst(ic) development/formation see also
Polycystic kidney disease
Cystic kidney disease, acquired 505
Cystinosis 517, 530
Cytochromes... 344, 345, 350, 360, 476, 600
Cytokines 594
Cytokines see also more specific entries
Cytomegalovirus infection ... 607, 608, 610,
611
Cytoplasmic viscosity 225
Cytoskeletal proteins 226, 531
Cytoskeletal proteins see also more specific
entries
Cytoskeleton 224, 226, 230
Cytoskeleton see also Microfilaments
Decay accelerating factor 431, 433
Decidua basalis 597
Decision analysis 482
Deferoxamine 273, 289, 292, 309, 451
Dehydration 549





DFMO (difluoromethylornithine)... 433, 434
Diabetes insipidus... 246, 250, 362, 499, 592
Diabetes meilitus
Complications . . . 241, 243, 245, 263, 280,
282, 301, 329, 398, 506, 610
Diet therapy 236
Drug therapy 401, 475, 483
Immunology 426
Pathology 436
Pathophysiology . 263, 274, 285, 339, 341,
347, 350, 501, 505, 509,
511, 512, 513, 522, 524,











Pathophysiology . 199, 221, 224, 236, 248,
285, 345, 360, 404, 502,
506, 507, 508, 510, 512,
513, 517, 519, 520, 521,
522, 523, 585, 588
Therapy 282
Diacyiglycerol kinase
Antagonists and inhibitors 208
Diacylglycerols 212, 206, 421, 431, 559
Dialysis... 239, 282, 309, 310, 315, 420, 448,
449, 451
Dialysis (hemodialysis)
Complications . . . 235, 237, 244, 283, 287,
289, 290, 291, 294, 298, 305,
309, 311, 312, 314, 316, 318,
320, 323, 325, 331, 334, 400,
403, 449, 450, 473, 492
Drug therapy. . . . 237, 289, 304, 307, 311,
319, 322, 324, 373
Immunology . 299, 302, 310, 322, 323, 436
Methods . . . 273, 290, 292, 293, 297, 302,
306, 313, 315, 379
Mortality 291, 301, 313, 324, 325
Outcome . . . 297, 300, 315, 318, 321, 322,
330, 333, 362, 368, 608
Pathophysiology . 288, 290, 294, 295, 297,
306, 312
Physiology . . 304, 311, 314, 317, 324, 340
Surgery 303
Therapeutic use 325
Dialysis see also Hemodiafiltration,
Hemoperfusion, Ramped hypertonic
sodium dialysis





Physiology 295, 310, 317
Dialysis, high flux






Dialysis, peritoneal 329, 331, 335
Drug therapy 331
Outcome 327, 332, 399
Pathophysiology 328
Dialysis, peritoneal (CAPD)
Complications. . . 244, 279, 309, 132, 326,
327, 328, 329, 331, 332, 333,
334
Drug therapy 326, 330
Epidemiology 330
Immunology 327, 329, 330, 436
Methods 332, 379, 455
Mortality 324, 330
Outcome 277, 326, 330, 333
Physiology 334
Rehabilitation 333
Dialysis, slow 313, 316, 320







Complications 288, 293, 295
646 Subject Index: Abstracts
Methods . . . 287, 288, 290, 291, 294, 297,


















Physiology 360, 382, 395, 524, 532
Therapeutic use 556
Dietary intake 384, 388, 589
Dietary intake of sodium 400, 411







Physiology. . 376, 501, 502, 503, 510, 528,
558, 615
Dietary proteins see also Protein restriction
Dihydropyridines 456






Distal tubules see under Renal tubules
(distal)
Diuresis 339, 341, 381
Drug effects 271, 338, 528, 583, 587
Physiology 270, 284
Regulation 369, 577, 580, 587, 592
Diuresis see also Natriuresis
Diuretics 561, 577
Diuretics see also more specific entries
(Bumetanide, Furosemide, Thiazides, etc.)
DNA
Antagonists and inhibitors 415
Biosynthesis 420
Drug effects 483
DNA see also cDNA
DNA repair 420
DOPA decarboxylase
Antagonists and inhibitors 363
Dopamine
Pharmacology 343, 370, 481
Physiology 359, 363, 378, 455, 522
Receptors 341, 368, 374, 379, 388
Therapeutic use 555
Dopamine see also Catecholamines
Doppler ultrasound 242, 616
Doppler ultrasound see also Ultrasound
imaging
Dosage forms 304
Drug delivery systems 527
Drug discontinuation 604
Drug interactions 333
Drug overdose 272, 302
Drug-induced nephropathies 259, 487











Pharmacology . . . 245, 347, 385, 498, 504,
508, 509, 511, 516, 518, 519,
520
Therapeutic use. . 236, 261, 278, 391, 401,
Encephalopathy in CRF
Diagnosis 305
Drug effects 293, 298
Etiology 289, 313, 320
Pathophysiology 306
End-stage renal disease
Complications . . . 236, 237, 240, 307, 312,
323, 449
Epidemiology 239, 241, 244, 252, 257,
270, 285, 404
Etiology 236, 248, 251, 257, 276
Mortality 239, 283, 325
End-stage renal disease see also Chronic
renal failure, Progression of renal disease
Endocytosis
Hormone effects 530
Physiology 415, 417, 589
Regulation 227, 341
Endoplasmic reticulum 216, 578
Endosomes 228
Endothelial cells 365, 385
Injuries 595, 599
Isolation and purification 194
Endothelin .... 190, 365, 367, 372, 373, 380,
385, 479, 587
Physiology. . 211, 282, 366, 369, 372, 373,
375, 376, 377, 379, 389, 400,
486
Receptors 203, 210, 363, 374
Endothelium-derived relaxing factor (EDRF)
Antagonists and inhibitors 387, 395
Physiology 203, 364, 371, 373, 379





Enzymuria see also Urinary enzymes
Epidermal growth factor
Physiology. . 190, 191, 194, 195, 196, 200,





Epinephrine see also Catecholamines







Abnormalities 258, 373, 488
Anatomy and histology 284
Drug effects 300
Immunology 409, 422, 432
Pathophysiology 316, 390, 499
Transport 502
Erythropoiesis
Drug effects 236, 330, 507
Pathophysiology 290
402 Erythropoietin
Administration and dosage. 235, 236, 240,
289, 311, 326,
330, 331, 379
Adverse effects. . . 237, 244, 278, 381, 396
Biosynthesis 374
Hormone effects 285, 301
Metabolism 366, 526
Pharmacokinetics 237, 331
Pharmacology. . . 213, 271, 290, 293, 300,
303, 304, 307, 321, 322, 507
Physiology 292, 308, 321, 387
Regulation 213
Therapeutic use. . 237, 240, 244, 245, 278,
279, 288, 293, 298, 299,
312, 313, 332, 368, 373,
378, 520, 551
Estrogens




Ethnic groups 257, 603, 614
N-Ethylmaleimide 228
Evoked potentials 293, 320
Exercise
Adverse effects 265, 275, 284
Drug effects 278
Outcome 333, 609
Physiology 265, 279, 311, 515
Extracellular matrix
Analysis 409
Anatomy and histology 223
Biosynthesis 195, 197
Growth and development 217, 218
Hormone effects 192, 219
Pathophysiology 440, 507
Physiology 218, 221, 222, 223
Receptors 223
Extracellular space 539








Fetal renal function 570, 572




Antagonists and inhibitors 254
Hormone effects 195
Fibroblasts










Therapeutic use 255, 437, 499, 614
Flow cytometry 287, 439, 527, 572
Fluorescent microscopy
Methods 252, 361
Fluorescent probes 206, 228, 390, 563
Fluorides 216
IMLP (formyl peptide) 215, 346
Focal/segmental sclerosis
Pathophysiology 498, 506, 507
Focal/segmental sclerosis see also
Glomerular sclerosis
Folic acid nephropathy 436
Fofficular cells 547
Fosinopril 397
Free radicals (reactive oxygen species)
Adverse effects . . 230, 428, 475, 476, 485,
496, 497
Biosynthesis. 294, 301, 306, 334, 407, 427,
429, 441, 498
Pharmacology 479
Physiology 363, 425, 490, 515, 522
Free radicals (reactive oxygen species) see
also Antioxidants, oxidative burst,
superoxide dismutase, xanthine oxidase
Frozen sections 602, 606
Fructose-i ,6-diphosphate 487
Furosemide 338, 550, 561
G proteins (guanine nucleotide binding
proteins)
Isolation and purification 214, 215
Pharmacology 214, 590








Gene expression ... 380, 411, 428, 560, 561,
566
Analysis 253, 355, 359, 484
Regulation . . 215, 219, 223, 229, 350, 354,
358, 370, 373, 580, 584
Gene expression see also Messenger RNA,
Transcription, Translation
Gene mapping 218, 521
Gene transfer 193, 202
Genes
Isolation and purification 191
Genes see also Oncogenes
Genetic counseling 250













Growth and development 416
Immunology . 410, 413, 423, 430, 431, 432
Pathophysiology 491
Glomerular filtration rate (GFR)
Analysis 241, 270, 277, 615
Drug effects . 345, 377, 425, 484, 489, 493,
497, 558, 599
Hormone effects 238
Regulation. . . 340, 378, 501, 510, 551, 593
Glomerular hemodynamics
Drug effects 382, 498, 520, 524, 594
Hormone effects 371, 550, 555
Pathophysiology 498, 500, 506, 514




Hormone effects 503, 504




Pathophysiology . 378, 382, 384, 418, 430,
433, 436, 483, 498, 507,
515, 517
Prevention and control. . . . 417, 504, 511,
518, 519
Therapy 556
Glomerular injury see also Renal injury,
autoimmune injury, reperfusion injury
Glomerular permeability 448, 507, 510









Pathophysiology. . 504, 506, 512, 518, 524
Prevention and control . . . . 508, 516, 523
Therapy 244, 332
Glomerular sclerosis see also
Focal/segmental sclerosis




Immunology 443, 444, 445
Pathology 446, 447
Pathophysiology.. 346, 352, 362, 498, 500





Glomerulonephritis, chronic .. 242, 392, 522
Glomerulonephritis, crescentic .... 249, 407
Glomerulonephntis, experimental 422,
423, 429
Diet therapy 437, 506
Drug therapy . . . . 418, 422, 427, 428, 519
Etiology 410
Immunology. 406, 408, 411, 412, 413, 414,
415, 416, 417, 418, 419, 423,
424, 425, 427, 428, 430, 432,
433, 434
Pathophysiology . 222, 410, 414, 415, 416,
418, 421, 422, 429, 434,
435, 500, 509, 515
Glomerulonephritis, fibrillary 440
















Anatomy and histology 238, 241
Antibody to 429
Drug effects 379
Growth and development 218, 338
Immunology 416, 422
Metabolism 376
Pathology. . . 408, 410, 411, 418, 419, 435,
447






Glucocorticoids 353, 548, 559
648 Subject Index: Abstracts
Receptors 425
Therapeutic use 419







Metabolism 462, 513, 521, 559
Physiology 221, 263, 381, 555
Transport 225, 230, 582




Glutathione 316, 525, 529
Glutathione peroxidase 290
Glycation 506









Glycoproteins 233, 418, 418
Glycoprotems see also more specific entries
(MAC-l, MAUP, fibronectin, etc.)
Glycosaminoglycans & proteoglycans.. 220,
222, 223, 495, 599
Glycosaminoglycans & proteoglycans see
also more specific entries
Glycosylation 200, 218
Glycosylation see also Glycation
Goldblatt kidney see under Hypertension,
animal models
Gonadotropin (GnRH) releasing hormone
Deficiency 276
Goodpasture's disease 409, 427, 446
G proteins (guanine nucleotide binding
proteins)
Isolation and purification 214, 215
Pharmacology 214, 590
Physiology. . 202, 213, 214, 215, 216, 217,
453, 561




Outcome 569, 607, 614
Growth disorders 240, 329
Growth factors 198, 200
Growth factors see also more specific




Physiology 460, 504, 513, 526
Therapeutic use 240, 329, 615, 616
Guanidines 514
Guanidinoacetic acid 531
Guanine nucleotide binding proteins see
under G proteins
Guanyl cyclase 364






Heart 340, 343, 545
Heart see also Myocardium
Heart diseases 280, 309, 517
Heart diseases see also Cardiac tamponade,
cardiovascular diseases, coronary artery
disease, pericardial effusion
Heart failure see under Congestive heart
failure
Heart transplantation 482, 607
Hematocrit 292, 296, 303, 390
Hematocrit see also Anemia
Hematuna 258, 284
Hemodiafiltration... 287, 308, 309, 316, 317,
318, 323




Drug effects 368, 484
Physiology 217, 317
Hemodynamics see also Glomerular
hemodynamics
HemotIlters 316
Hemofiltration 286, 309, 317, 318
Hemoglobins 373
Hemolytic-uremic syndrome 254, 438
Hemoperfusion 272, 273, 302
Hemorrhage 550
Hemostasis see under Blood coagulation
physiology
Henoch-Schoenlein purpura 439
Heparan sulfate 194, 198, 421
Antibody to 445




Hepatitis B nephropathy 447
Hepatitis B vaccine 438, 442
Hepatitis, non-A, non-B 298, 303, 320
Hepatocytes 514
Hepatotoxicity 472
Hepatotoxicity see also Liver
Heredofamilial diseases 220
Heredofamilial diseases see also Alport's
syndrome, polycystic kidney disease
12-HETE (Hydroxyeicosatrienoic acid). 208
Heymann nephritis see under
Glomerulonephritis, experimental
HgCl2 nephropathy.. 407, 421, 432, 485, 491
HgCI2nephropathy
see also Mercury compounds
High efficiency dialysis see under Dialysis,
high efficiency
High flux dialysis see under Dialysis, high
flux
High salt diet 388, 394





Histamine (H2) antagonists 597
Histidine 360, 365
Histocompatibility antigens .. 251, 406, 424,
438, 596
Histones 430
HIV infection 254, 307, 315, 330, 439
HIV infection see also AIDS
Hollow fibers 297, 301, 316, 317, 323
Home care 240, 328, 333
Hospitalization 241, 291, 311, 328
Host-versus-graft disease 406
HTLV infection 314
Hybridization .. 192, 193, 229, 230, 248, 253




Hydrogen ion 529, 533, 541
Transport. . . 232, 234, 535, 536, 538, 546,
548, 568, 569, 593
Hydrogen ion see also Antiport, Na/H
Hydrogen ion concentration 467
Hydrogen peroxide 376
Hydrogen peroxide see also Free radicals
Hydrostatic pressure 558
Hydroxyapatites 472
12-HETE (Hydroxyeicosatrienoic acid). 208
Hyperaldosteronism 397, 465






Pathophysiology 502, 512, 519, 520
Hyperfiltration 371, 397
Pathophysiology . 235, 245, 341, 374, 402,
501, 502, 503, 510, 512,















Pathophysiology . 287, 502, 503, 509, 512,
514










Hyperosmolality see also Osmolarity
Hyperosmolality-induced protein 576
Hyperoxaluria 274




Drug therapy 450, 465, 468
Pathophysiology 299, 448, 467
Surgery 283, 296, 449
Hypersulfatemia 267
Hypertension
Complications 236, 244, 285, 404
Diagnosis 398
Drug effects 278
Drug therapy. . . . 245, 278, 397, 398, 401,
402, 516
Epidemiology 277, 603
Etiology. . . . 237, 244, 251, 276, 279, 396,
401, 403
Genetics 384
Pathophysiology . 209, 251, 271, 277, 283,
314, 340, 342, 384, 387,
390, 392, 393, 394, 397,
398, 399, 400, 401, 402,
403, 404, 405, 499, 514




Diet therapy 360, 411
Drug effects 480
Drug therapy 509, 582
Immunology 431
Pathophysiology . 359, 371, 372, 484, 420,
511
Hypertension, animal models
(Goldblatt kidney). 389, 390, 428, 498, 558
Hypertension, animal models (inbred
strains)
Diet therapy 387, 388
Drug therapy 518, 520, 523
Mortality 394
Pathophysiology . 336, 382, 383, 384, 385,
386, 387, 388, 389, 390,
391, 392, 393, 394, 395,
Hypertension, animal models, NaDOCA
(salt loading/deoxycorticosterone) ... 389,
395
Hypertension, malignant 399









Hypochloremia see also Alkalosis,
metabolic
Hypogonadism 276













Hypoxia see also Anoxia, ischemia,
reperfusion injury
Ibuprofen 271
ICAM-l (intercellular adhesion molecule-l)
437, 506
Idiopathic interstitial nephritis see under
Interstitial nephritis, idiopathic
IgA deficiency 410














Physiology . . 409, 413, 432, 433, 439, 440
Immune response ... 436, 438, 442, 444, 446
Immune response see also Antibody
formation











Immunoglobulins see also IVIG




Pathophysiology 414, 596, 598, 613
Regulation 363
Immunologic receptors 218, 424, 430
Immunosuppressive agents 609
Immunosuppressive agents see also more
specific entries
Immunosuppression 596, 609
Outcome . . . 406, 420, 421, 433, 434, 483,
599, 608
Pathophysiology 606
Therapeutic use 604, 614
Immunosuppression see also specific
therapeutic agents
Immunotherapy 435, 478
Immunotherapy see also OKT3
immunotherapy
Indomethacin 348, 352, 577
Adverse effects 398, 497
Pharmacology 347, 503, 558
Infection control 331
Inflammation 416, 417, 428
Influenza vaccine 446
Inositol 532, 576, 586, 588
Inositol phosphates
Antibody to 208
Biosynthesis 199, 204, 532
Physiology 212, 413
Inositol transport, sodium dependent... 588
Insulin
Administration and dosage 261
Metabolism 530
Physiology. . 190, 195, 380, 381, 452, 505,
508, 521, 573
Receptors 201
Secretion 462, 466, 505, 513
Insulin-like growth factor
Physiology 201, 370, 380, 504, 513
Receptors 522, 526
Urine 376
Insulin resistance 381, 386
Integrins
Receptors 223
Intercalated cells 231, 540
Physiology 227, 234, 536, 545





Biosynthesis . 288, 301, 319, 330, 408, 436
Diagnostic use 602, 609
Immunology 409, 601
Pathophysiology 406
Physiology. . 193, 204, 205, 307, 349, 364,
369, 418, 426, 436, 445, 606
Receptors. . . 299, 407, 431, 438, 439, 500,
599, 601
Secretion 411, 422, 608
Interstitial fibrosis 518, 521
Interstitial nephritis, idiopathic 255
Intestinal absorption .... 353, 399, 457, 471,
472, 473, 474, 546
Intracellular pH 385, 393, 540, 560, 574
Regulation . . 191, 199, 361, 388, 391, 530,
535, 537, 540, 541, 544, 562,
569
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Intradialytic hypotension 319, 325
Ion channels 192, 199, 561








Islets of Langerhans 466
Isoproterenol 396
IVIG (IV immunoglobulin preparations). 280,
441
Joint diseases 287, 296, 519
Kallikrein






Growth and development. . 358, 388, 533,
542, 546, 559
Kidney see also more specific entries (Renal
cortex, medulla, etc.)
Kidney function tests 270, 277





Laininin 223, 407, 440
Latex photometric immunoassay 276
Lectins 234, 407, 413, 440
Left ventricular hypertrophy 288
Leukemia 260
Leukocytes 278
Leukocytes see also more specific entries
(Neutrophils, lymphocytes, etc.)
Leukotnenes
Biosynthesis 329, 346, 352, 421
Immunology 434








Physiology 501, 502, 509, 514, 608
Lipoxins 347, 351
Lipoxygenase
Antagonists and inhibitors 395, 421
Physiology 368
Liquorice (licorice) 357
Lisinopril 239, 503, 508
Lithium











Liver diseases 270, 341, 487, 496
Liver transplantation 373, 403





Physiology. . 380, 461, 472, 474, 536, 542,
572, 577, 586















Drug therapy 238, 256, 442
Immunology 411, 444, 447
Pathology 419, 437
Pathophysiology 351, 414, 424
Lymphocyte activation 410, 435, 436
Lymphocytes 281, 303, 393, 434







Immunology. 419, 420, 423, 426, 428, 429,
599, 600
Pathophysiology. . 435, 439, 5%, 598, 606
Physiology 208, 436, 595, 596, 601
Lymphokines 600
Lysosomes 527
MAC-l glycoprotein 308, 438
Macrophages... 327, 330, 385, 387, 465, 504
Macula densa 357, 381, 561, 565











Magnetic resonance imaging (MRI) .... 275,
281, 282, 492, 556
Magnetic resonance spectroscopy.. 280, 461







Mean corpuscular volume 289
Medulla, renal see under Renal medulla
Membrane fluidity.. 207, 209, 225, 457, 499,
580
Membrane potentials .... 281, 366, 468, 533
Membrane potentials see also Cellular
electrophysiology
Membrane proteins
Biosynthesis 218, 219, 221
Genetics 539
Immunology 429, 445
Isolation and purification .. 214, 227, 231,
233, 234
Membranes see also Dialysis membranes




Membranous glomerulonephritis see under
Glomerulonephritis, membranous
Mercury compounds 421, 488
Toxicity 292, 491
Transport 190, 202, 457
Mercury compounds see also HgCl2
nephropathy
Mesangial cells 192, 229, 378, 507
Anatomy and histology 218, 227
Drug effects 434, 508





Hormone effects 197, 201, 204
Immunology 407, 418, 430, 431, 433
Metabolism 219, 220, 221, 222, 223
Pathophysiology 420, 431, 502
Physiology. . 195, 210, 214, 215, 217, 363,
368, 376, 385, 387, 408, 426,
472, 506, 514, 551, 563, 567
Mesangial proliferative glomerulonephritis
see under Glomerulonephritis, mesangial
proliferative
Mesenteric arteries 387
Messenger RNA see under mRNA
Metabolic cidosis see under Acidosis,
metabolic
Metabolic alkalosis see under Alkalosis,
metabolic
Metal nephropathy 477, 478, 485
Metalloproteinases
Antagonists and inhibitors 595
Metals 582
Subject Index: Abstracts 651
Metals seealso more specific entries
(Cadmium, mercury, etc.)
N-Methyl arginine 371, 395, 552
Methylguanidine 515, 522
Methyltransferases
Antagonists and inhibitors 198
Metolazone
Analogs and derivatives 566
Metyrapone 274
Microcirculation see under Renal capillaries
Microfilaments 226, 228, 482
Microfilaments see also Cytoskeleton, actin,
etc.
microglobulin
Biosynthesis 303, 320, 325
Blood 290
Diagnostic use 296, 602
Physiology 297, 304, 315
Microscopy in vivo 549




Migration inhibition factor 426
Mineralocorticoids 342, 357, 403, 588
Mineralocorticoids see also Aldosterone
Minimal change disease . 242, 260, 281, 448,
507




Anatomy and histology 224, 227
Metabolism 487, 528
Pathology 206
Mitogens 204, 251, 442




Diagnostic use 225, 344
Immunology 418




Monocytes 310, 424, 426
Morphogenesis 194, 217
Morphogenesis see also Kidney (growth and
development)
Morphometry 241, 246, 411, 419, 491
mRNA.... 201, 220, 229, 470. 532, 580, 581
Multiple myeloma see also Paraproteinemias
Multiple myeloma 247, 276
Multiple myeloma see also Myeloma cast
nephropathy





Muscles 265, 531, 569
Myeloma cast nephropathy 276, 494
Myeloma cast nephropathy see also Multiple
myeloma
Myocardium 510, 516
Myocardium see also Heart
Myocytes 505
Myosin 230
Na/Ca exchange (antiport) seeunder
Antiport, Na/Ca +Na/H exchange (antiport) see under
Antiport, Na/H
Na/K exchange (antiport) see under
Antiport, Na/K




Drug effects. . 268, 271, 337, 341, 355, 390
Hormone effects 381, 383, 403
Pathophysiology 384, 389
Physiology 284, 341, 342, 565, 574
Regulation . . 337, 339, 342, 349, 350, 352,
356, 357, 358, 363, 375
Natriuresis see also Diuresis
Neoplasms
Complications 254
Neoplasms see also more specific entries




Outcome 277, 383, 420, 574
Pathophysiology 200
Nephrectomy see also Remnant kidney
function
Nephrocalcin
Diagnostic use 439, 443
Physiology 471, 474
Nephrons 275, 421, 510, 560
Nephrons, superficial 232
Nephrotic syndrome
Complications 243, 256, 283
Congenital 277
Diet therapy 243
Drug therapy . . . . 255, 261, 262, 451, 503
Etiology 254, 256, 260
Immunology 439, 445
Outcome 257
Pathophysiology . 253, 260, 342, 345, 356,
417, 503, 507, 509, 512,
524, 527, 574
Therapy 277
Nephrotic syndrome see also Minimal
change disease, puromycin
aminonucleoside nephrosis
Nephrotoxic nephritis see under
Glomerulonephritis, experimental
Nephrotoxicity







Pathophysiology . 190, 376, 420, 475, 477,
478, 480, 483, 484, 485,
488, 489, 492, 493, 494,
495, 497
Nephrotoxicity see also specific substances
(toxicity)
Nerve growth factor 198
Neutrophil activating factor 362
Neutrophil function
Drug effects 322, 595
Hormone effects 407
Pathophysiology . 299, 301, 322, 329, 441,
476
Physiology 334, 413, 551
Regulation 346, 413, 494
Neutrophil function see also Oxidative burst
Neutrophils
Immunology 413, 442
Pathophysiology 255, 302, 308, 323
Nifedipine
Pharmacology 299, 504, 595
Therapeutic use 239, 242, 402, 597
Nitrendipine 260
Nitric oxide see also Methyl arginine







Physiology . . 302, 367, 3%, 534, 552, 559
Secretion 269
Norepinephrine see also Catecholamines
Nucleoproteins 423, 430, 434
Obstructive arterial diseases 318
OKT3 immunotherapy








Organ preservation 5%, 609
Organ preservation see also Renal
transplantation
Organ procurement 613, 615
Ornithine decarboxylase




Osmolar gap see also Anion gap
Osmolarity.... 1%, 274, 279, 284, 537, 572,
576, 585, 586
Osmolarity see also Hyperosmolality
Osteitis fibrosa 450, 465





652 Subject Index: Abstracts
Ouabain-like factor see also ATPase
inhibitor(s)
Ovarian carcinoma 489
Oxalates 274, 284, 291, 516, 577, 587
Oxalates see also Calcium oxalates,
hyperoxaluria
Oxidative burst 305, 323, 413, 432
Oxidative burst see also Free radicals
Oxidative injury (stress)
Pathology 497
Pathophysiology . 230, 305, 306, 316, 427,
428, 429, 475, 483, 488,
490, 491, 493, 501, 502,
514, 522, 525
Prevention and control 525
Oxidative injury (stress) see also
Antioxidants, free radicals, renal
ischemia, reperfusion injury
Oxygen consumption 476, 527, 528














Paraproteinemias see also Multiple myeloma
Parathyroid cells 469
Parathyroid glands 436, 450
Parathyroid hormones ... 293, 314, 450, 466
Antagonists and inhibitors 464
Pharmacology 481, 587
Physiology. . 196, 202, 205, 210, 211, 285,
294, 295, 301, 302, 304, 324,
380, 454, 458, 459, 460, 463,
464, 465, 466, 467, 468, 469,








Pars convoluta see under Renal tubules
(pars convoluta)
Pars recta see under Renal tubules (pars
recta)
Pediatric dialysis see under Dialysis,
pediatric






Antagonists and inhibitors 337
Peptide receptors 342
Hormone effects 336
Isolation and purification... 335, 337, 344
Pathophysiology 339, 342













Epidemiology. . . . 256, 326, 329, 330, 333
Prevention and control 331, 335
Permselectivity 506, 513, 612
Drugeffects 261,508,516,519
Permselectivity see also Cell membrane,
glomerular permeability
Pertussis toxin 463, 561
pH, intracellular see under Intracellular pH
Phiorizin 585, 589
Phorbol esters 192, 212, 349, 470
Phosphatases 496
Antagonists and inhibitors 368
Phosphate binders... 2%, 449, 450, 455, 584
Adverse effects 305, 328
Physiology 462, 474
Phosphate restriction.... 246, 453, 457, 460,
463, 469, 552
Phosphate transport, sodium dependent. 190,




Physiology. . 302, 449, 453, 454, 458, 459,
461, 462, 469, 518, 568
Transport. . . 452, 453, 455, 456, 457, 459,
460, 465, 586, 587




Isolation and purification 362
Phosphoenolpyruvate carboxykinase ... 197
Phosphoinositides 206, 208, 232, 580
Phospholipase A2... 194, 206, 312, 472, 488
Phospholipase C
Hormone effects 199, 203
Metabolism 200
Physiology 193, 202, 213, 336, 364
Phospholipase D 208
Phospholipases 478, 492
Phospholipids 213, 486, 490, 333
Phosphonoformic acid 455, 459
Phosphorus see under Phosphates
Phosphorylation 194, 209, 230, 560








Plasmapheresis 288, 297, 325
Plasminogen activator inhibitor ... 219, 254,
435
Plasminogen activators 195, 286, 428
Platelet activating factor
Antagonists and inhibitors 378




Platelet aggregation 287, 321, 512
Platelet-derived growth factor 192, 194,
199, 200, 203,
204, 408, 414
Platelets 209, 367, 412, 417




Polyamines 240, 433, 434
Polycystic kidney disease.... 200, 247, 250,
425, 566, 605
Complications. . . 249, 251, 252, 253, 397,
502
Diagnosis 247, 249, 251
Genetics. . . . 247, 248, 249, 250, 253, 521
Outcome 238, 248, 251, 252
Pathophysiology . 1%, 225, 229, 247, 253,
292, 380, 412
Polycystic kidney disease see also Cyst(ic)
development formation
Polycythemia 612




Potassium 266, 563, 590
Drug effects 268, 558
Physiology 379, 459, 562, 569, 571
Therapeutic use 384, 387
Transport. . . 363, 560, 563, 564, 568, 573,
574, 575
Potassium channels
Physiology. . 562, 563, 564, 565, 566, 567,
568, 570, 571, 573, 574, 576
Potassium/bicarbonate symport 541
Prazosin 608
Prednisone 262, 240,451, 603, 604, 614
Prednisone see also Glucocorticoids,
immunosuppression
Pregnancy 354, 550, 571
Pregnancy complications. 263, 277, 392, 558
Principal cells 540, 548
Procoagulant activity 446
Procollagen 508, 511
Biosynthesis 224, 521, 598
Progression of renal disease
Diagnosis 241, 242, 249, 255
Drug effects 279, 402
Pathophysiology 424, 499
Prevention and control 239
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Progression of renal disease see also





Prostaglandin synthase see under Cyclo-
oxygenase
Prostaglandins
Biosynthesis. 195, 345, 348, 349, 351, 352,
365, 371, 376, 377, 503, 595
Drug effects 558, 594
Pharmacology 398, 579
Physiology.. 209,211,212,225,344,349,








Hormone effects 199, 385
Pharmacology 209, 576, 582, 589
Physiology. . 190, 192, 199, 202, 205, 207,
216, 234, 453, 456, 527, 541,
544, 560, 567
Protein kinases see also Phosphorylation
Protein restriction 246, 511
Outcome 239, 243, 271, 357, 531
Physiology 272, 500, 506
Therapeutic use 549, 612
Protein restriction see also Dietary proteins
Protein S 381
Protein structure 232
Protein synthesis 477, 490, 521, 583
Protein synthesis see also more specific
entries (biosynthesis)
Proteinases 520
Proteins see under more specific entries
(Dietary proteins, etc.)
Proteins, low molecular weight 527
Proteinuria 503, 523, 574
Drug therapy 255, 395, 509
Drug effects . 235, 236, 239, 261, 262, 397,
498, 503, 508
Etiology 243, 428, 433, 512
Pathophysiology . 377, 385, 392, 404, 408,
412, 418, 419, 448, 497,
501, 507, 519










Purinergic receptors 202, 584
Puromycin aminonucleoside
Analogs and derivatives 198
Puromycin anunonucleoside nephrosis . 218,
219, 412, 431, 466, 488, 491, 498, 504, 522
Puromycin aminonucleoside nephrosis see
also Nephrotic syndrome
Pyelonephritis 512




Quality of life 278
Radioimmunoassay 466
Radionuclide imaging 242, 296
Ramped hypertonic sodium dialysis .... 306
Ranitidine 316, 456
Rapidly progressive glomerulonephritis see
under Glomerulonephritis, rapidly
progressive
Reactive oxygen species see under Free
radicals
Recirculation 297
Reflux nephropathy 276, 279












Prevention and control . . . . 604, 606, 608
Rejection (renal allograft) see also Renal
transplantation





Pathophysiology 500, 518, 525, 554
Physiology 355
Remnant kidney function see also
Nephrectomy
Renal adaptation 401, 569
Renal arteries 386, 550, 598
Renal artery stenosis
Complications 505




Drug effects 477, 484, 555, 582
Hormone effects 557
Pathophysiology 554
Regulation 346, 355, 550, 552, 558
Renal blood flow see also Glomerular
filtration rate
Renal blood flow see also Glomerular
hemodynamics
Renal capillaries
Drug effects 485, 497
Injuries 406, 436
Physiology 353, 356, 551
Renal cortex
Genetics 528
Growth and development . . 372, 542, 561
Physiology 460, 553, 554
Ultrastructure 229
Renal failure see under Acute, Chronic renal
failure
Renal hypertrophy 196, 201, 261, 508
Etiology 224, 553
Pathophysiology . 193, 195, 201, 204, 511,
518, 522
Renal injury 258, 376, 413
Renal injury see also Autoimmune,





Drug therapy 495, 497
Outcome 485, 496
Pathophysiology . 476, 479, 480, 481, 482,
484, 488, 489, 492, 493,
494, 495, 497, 532, 549




Growth and development 542
Physiology 364, 411, 553, 586
Renal medulla, inner zone 343
Renal medulla, outer zone .... 476, 528, 588
Renal neoplasms
Diagnosis 443






Physiology 454, 554, 570
Renal osteodystrophy




Pathophysiology 295, 449, 450, 456
Prevention and control 296
Surgery 296
Renal papilla 336
Renal reserve 402, 404, 557, 614
Renal scars 276, 512
Renal transplantation
Complications. . . 249, 266, 397, 398, 400,
401, 603, 604, 605, 607, 611,
612, 613
Drug therapy . . . . 495, 595, 604, 608, 614
Immunology 594
Mortality 239
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Renal transplantation see also Delayed,
early graft function, Organ preservation,
procurement, rejection,
xenotransplantation
Renal transplantation, cadaveric .. 603, 609,
611, 612
Renal transplantation, pediatric 602,
603, 604, 605, 607, 611, 612, 614, 615, 616
Renal transplantation, second 611
Renal tubular acidosis see under Acidosis,
renal tubular
Renal tubules
Growth and development 198, 478,
484, 485, 490, 492
Physiology 259, 474, 575, 579
Radionuclide imaging 225




Physiology. . 203, 206, 216, 217, 343, 361,
362, 536, 538, 541, 542, 548,
549, 562, 564, 576, 577, 578,
580, 581, 584, 585
Renal tubules (distal)
Anatomy and histology 454
Immunology 424
Physiology 461, 464, 471
Transport 559
Renal tubules (pars convoluta) 224, 530
Renal tubules (pars recta) 458
Renal tubules (proximal)
Anatomy and histology 527
Drug effects 379
Growth and development. . 192, 197, 199,
204, 368, 380
Hormone effects 211, 469, 508, 537
Immunology 416, 417, 423
Injuries 500, 529
Isolation and purification 525
Metabolism 429, 526, 527, 528, 531
Pathology 226
Pathophysiology . 267, 511, 517, 522, 526,
571
Physiology. . 214, 217, 371, 453, 456, 461,
462, 467, 471, 474, 525, 528,
531, 533, 536, 539, 540, 543,
559, 568, 576, 581, 591
Ultrastructure 206, 487, 495
Renal veins 264
Renin. 352, 354, 355, 357, 358, 362, 383, 522
Physiology . 345, 353, 356, 357, 361, 381
Renin-angiotensin system
Drug effects 338
Pathophysiology 397, 428, 509
Physiology 339, 356, 359, 389
Regulation. . . 352, 353, 354, 355, 358, 360
Renovascular hypertension see under
Hypertension, renovascular
Renovascular hypertension see also
Hypertension, animal models (Goldblatt
kidney)
Reperfusion injury 479, 482, 496, 497
Reperfusion injury see also Oxidative injury
(stress), Renal ischemia, Renal injury,
glomerular injury
Resident education 613
Residual renal function 312
Resistance genes 234
Respiratory acidosis see under Acidosis,
respiratory
Respiratory alkalosis see under Alkalosis,
respiratory
Restriction fragment length polymorphisms
246
Retinoic acid 195
Rhabdomyolysis 269, 270, 275, 284




Rifampin 327, 333, 335
















Deficiency 290, 472, 473
Sepsis 263, 278, 305, 307, 476, 487






Sex differences 268, 269, 347
Shock 485
SHR rats see under Hypertension, animal
models
Shunt stenosis 311, 319, 324
Shunt thrombosis ... 278, 286, 308, 305, 324
SIADH 266, 589
Sicca-like syndrome 315
Signal transduction (intracellular) . 198, 202,
203, 205, 208, 210, 213, 214, 215, 216, 431,
442, 468
Signal transduction (intracellular) see also
more specific entries (Adenyl cyclase,
Cyclic AMP, Diacylglycerols, G proteins,
etc.)
Simian virus 201
SKF 105494 583, 587
Sleep apnea 323
Slow dialysis see under Dialysis, slow
Sodium 266, 529, 575, 589
Adverse effects 369, 384
Diagnostic use 267
Intracellular 525
Physiology. . 337, 383, 388, 393, 397, 403,
458, 571, 572
Regulation 217, 356, 453
Transport. . . 229, 260, 263, 337, 353, 358,
359, 366, 372, 452, 453, 456, 458,
460, 464, 465, 499, 502, 529, 533,
535, 563, 573, 575
Sodium see also Antiport, Na/Ht etc.
Sodium see also Dietary intake of sodium,
high salt diet, salt appetite
Sodium bicarbonate 267
Sodium channels... 208, 209, 213, 217, 233,
561, 563, 564, 565, 574
Sodium chloride.... 338, 370, 392, 393, 411,
562, 586
Sodium-deoxycorticosterone model see
under Hypertension, animal models
Sodium, fractional excretion of ... 400, 522,
610
Sodium restriction 395, 511, 561, 565
Sodium retention 270, 277, 571, 574
Sodium/amino acid symport... 209, 477, 593





Sodium/glucose symport 477, 589
Sodium/inositol symport 584
Sodium/D-mannose symport 585




Sodium/taurine symport 578, 583, 591




Spinal artery occlusion 325
Splenectomy 488
SQ-29852 394
Staphylococcus 289, 327, 328, 331, 333
Statistical analysis 249, 265
Stroke 388, 394









Superoxide see under Free radicals
Superoxide dismutase 490
Suppressor function 596, 601




Tamm Horsfall protein 255, 427, 462
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Taurine 578, 591





Theophyiline see also Aminophylline
Thiazide receptors 562, 566
Thiazides 516, 566





Thrombotic thrombocytopenic purpura . 325
Thromboxane synthetase
Antagonists and inhibitors 415, 501
Thromboxanes 347, 351, 424, 484, 604








Thyroid hormones 336, 377, 485, 489
Ticlopidine 424




Transcription (genetic) .. 197, 201, 220, 222,
319, 521
Transcription (genetic) see also Gene
expression, mRNA
Transferrin 449




Transplantation see under specific organ
(transplantation)
Transplantation, renal see under Renal
transplantation
Transport see under specific substance
(transport)
Transport see also Antiport, Cellular
transport mechanisms, Endocytosis
Transport inhibitors, experimental 460




Tubular reabsorption.... 235, 263, 355, 363,
458, 460, 517, 522, 537,
541, 542, 545, 548, 572,
573, 575, 579, 590, 592
Tubular defects 526
Tubular epithelial cells 380
Tubular secretion 541, 543, 546, 577
Tubules see under Renal tubules
Tubuloglomerular feedback
Drug effects 245, 494
Physiology 549, 554, 555, 557
Tubulointerstitial diseases.... 198, 254, 412,
498
Tumor markers 439, 443
Tumor necrosis factor 363, 409
Biosynthesis. 288, 301, 310, 315, 319, 329,
417, 597, 600
Diagnostic use 597
Physiology. . 205, 215, 307, 345, 414, 422,
435, 445, 606
Receptors 407
Tyrosine kinases 194, 374
Ultrafast dialysis see under Dialysis,
ultrafast
Ultrasound imaging 251, 326, 450




Urea 528, 578, 586, 590
Urea kinetics 300, 399
Analysis 295, 315, 332, 334
Diagnostic use 326
Physiology 304, 579
Uremia 463, 511, 513
Complications . . . 240, 244, 276, 306, 315,
318, 502, 517
Drug therapy 274, 509, 523
Immunology 322, 442, 446
Pathophysiology . 212, 280, 470, 500, 502,
505, 510, 513, 515, 516,
520 526, 600
Uremia
see also Chronic renal failure, end-stage
renal disease
Uric acid 259, 400, 475
Urinary acidification .... 226, 228, 264, 266,
464, 494
Urinary acidification see also Acid-base
regulation
Urinary enzymes 258, 276
Urinary enzymes see also Enzymuria
Urinary tract infections 272
Urinary tract infections see also
Pyelonephritis
Urinary tract obstruction 262, 490
Pathophysiology. . 339, 352, 375, 461, 484
Urolithiasis
Drug therapy 587
Pathophysiology . 222, 274, 282, 284, 462,
468, 471, 472
Prevention and control 459
Therapy 412





Vascular access 303, 310






Regulation 360, 554, 555
Vascular smooth muscle
Embryology 220
Growth and development 200, 204
Physiology. . 337, 359, 364, 374, 385, 386,
387, 388, 391, 396
Vasculitis
Diagnosis 281, 440, 443
Immunology 441, 442, 444
Pathology 437
Vasculitis see also Takayasu syndrome
Vasoactive intestinal peptide 371, 534
Vasoconstriction
Drug effects 375, 391, 598
Hormone effects. . 366, 367, 372, 386, 551
Regulation 347, 351, 354, 479, 552
Vasodilat ion 347
Vasopressins
Antagonists and inhibitors . 348, 367, 579,
583, 587, 589
Genetics 266
Isolation and purification 361
Pharmacology. . . 207, 225, 362, 581, 583,
586, 588, 592, 593
Physiology. . 191, 203, 204, 205, 206, 212,
231, 262, 274, 279, 317, 338,
343, 360, 361, 365, 380, 395,
476, 499, 574, 576, 579, 580,
582, 584, 585, 587, 589, 592
Receptors. . . 191, 194, 201, 250, 361, 362,
367
Vasopressins see also SIADH
Vasoreactivity 369, 493
Venous pressure 311




Pharmacology 486, 521, 558
Therapeutic use 319, 401
Vesicoureteral rellux 262, 271, 276
Vesicoureteral reflux see also Refiux
nephropathy
Viscosity 271
Vitamin B6 291, 324
Vitamin D
Analogs and derivatives 463, 467
Metabolism 391, 466
Physiology 456, 468, 469, 473
Therapeutic use 463





Physiology . . 336, 358, 550, 565, 570, 571
Therapeutic use 341
von Hippel-Lindau syndrome 242
von Wilebrand factor 322, 361, 602
von Willebrand factor see also Blood
coagulation factors
Water. 209, 336, 366, 580, 581, 583, 588, 589
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Water channels
Hormone effects 589
Physiology 226, 231, 593
Regulation 582, 583, 588






Water, fractional excretion of 401
Water immersion 401
Water intake 265




Xanthine oxidase 479, 480, 482, 491
Xanthine oxidase see also Free radicals,
antioxidants
Xenoreactive antibodies 601
Xenotransplantation 601
Yersinia enterocolitica 423
Zeranol 523
Zidovudine 307
Zinc
Deficiency 330
Metabolism 473
